pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$NTLAIntellia Therapeutics, Inc.

$NTLA9.7000-8.06%
Cambridge, MA, USupdated 3d ago

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
lonvoguran
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 5, 2026
earnings
$NTLA9.7000-8.06%
12d ago
Intellia Therapeutics, Inc. earnings
Intellia Therapeutics, Inc.
→
view all catalysts →

Active trials

  • —Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001enrolling by invitationn=72
  • phase3HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)active not recruitingn=80
  • phase3A Phase 3 Study of NTLA-2001 in ATTRv-PNrecruitingn=60
  • phase3MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)recruitingn=1,200
  • phase2NTLA-2002 in Adults With Hereditary Angioedema (HAE)active not recruitingn=37
  • phase1Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)completedn=72
  • —Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002enrolling by invitationn=100
  • phase2NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Diseasewithdrawn
🐶 Hiring Signal
No open roles indexed yet — view Intellia Therapeutics, Inc. jobs →

News

  • ‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban
    Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and C…
    biospace · 1mo ago
  • ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
    Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
    biopharma_dive · 3mo ago
  • Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
    Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
    biopharma_dive · 5mo ago
identifiers
ticker
$NTLA
SEC CIK
0001652130
country
US
source
sec_tickers
top tags
Immunology1
mentioned in
3news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 6m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?